The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810. It tests the use of Atorvastatin Calcium Tablets for detoxification and prevention of blood acidification, and the use of the Chinese herb compounded Anti-Viral Granules for the detoxification in the endocrine system.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
The intervention observes the effects of the medicines on the participant's health without the continued interventions on blood pressure. Rescue medicines will be used once if the blood pressure rise again beyond the healthy range.
Residential Address
Chongqing, Chongqing Municipality, China
Total Cholesterol Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that total cholesterol levels indicate to the initial acidification for SARS-CoV-2 viral entry through vaccines with the degeneration of lipids.
Time frame: 30 days
Triglycerides Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that triglycerides levels indicate to the initial acidification for SARS-CoV-2 viral entry through vaccines.
Time frame: 30 days
HDL-C Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
LDL-C Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication. It is hypothesized that SARS-CoV-2 hibernating viruses and viral proteins are hidden in the LDL-C.
Time frame: 30 days
Apolipoprotein A-I Change
Time frame: 30 days
Apolipoproteina B Change
Time frame: 30 days
Lipopoliproteina (a) Change
Time frame: 30 days
Eosinophil Absolute Number Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Eosinophil Percentage Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Basophil Absolute Number Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Basophil Percentage Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Mean Corpuscular Volume Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Mean Corpuscular Hemoglobin Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Mean Corpuscular Hemoglobin Concentration Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Red cell Distribution Width Coefficient of Variation Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Red cell Distribution Width Standard Deviation Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Plateletcrit Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Platelet Distribution Width Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Mean Platelet Volume Change
The baseline characteristics is set at the beginning of the trial, with its rate of change metrified from initial intoxication.
Time frame: 30 days
Heart Rate Change
The blood pressure change will be compared with the baseline characteristics for observation on the risks of rebound to the previous intervention. Type I error testing defines Systolic \& Diastolic Blood Pressure and heart rate as incremented. Heart rate variance indicates to immune responses.
Time frame: 4 hours
Systolic Blood Pressure Change
The blood pressure change will be compared with the baseline characteristics for observation on the risks of rebound to the previous intervention. Type I error testing defines Systolic \& Diastolic Blood Pressure and heart rate as incremented. SBP variance indicates to infection activities.
Time frame: 4 hours
Diastolic Blood Pressure Change
The blood pressure change will be compared with the baseline characteristics for observation on the risks of rebound to the previous intervention. Type I error testing defines Systolic \& Diastolic Blood Pressure and heart rate as incremented. DBP variance indicates to immune attack activities.
Time frame: 4 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.